Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Early research (Phase 1)Ended earlyNCT03082300
What this trial is testing

ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor (EGFR) Mutations
Astellas Pharma Global Development, Inc. 3
Large-scale testing (Phase 3)UnknownNCT05104281
What this trial is testing

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Qingdao Central Hospital 60
Not applicableAvailableNCT07601399
What this trial is testing

An EAP Treatment Protocol of Zipalertinib

Who this might be right for
Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Not applicableStudy completedNCT02321046
What this trial is testing

An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 26
Testing effectiveness (Phase 2)Looking for participantsNCT07329322
What this trial is testing

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 30
Testing effectiveness (Phase 2)Study completedNCT04075396
What this trial is testing

Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 29
Not applicableUnknownNCT00903292
What this trial is testing

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Non-Small Cell Lung Cancer
National Cheng-Kung University Hospital 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144
What this trial is testing

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Testing effectiveness (Phase 2)Looking for participantsNCT07699328
What this trial is testing

VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
EGFR-Mutant Non-Small Cell Lung Cancer
Voronoi, Inc 315
Testing effectiveness (Phase 2)Looking for participantsNCT07485452
What this trial is testing

Boosting Osimertinib Blood Brain Barrier Penetration

Who this might be right for
Non-Small Cell Lung Cancer
Maastricht University Medical Center 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT03381274
What this trial is testing

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedImmune LLC 43
Large-scale testing (Phase 3)Looking for participantsNCT06350097
What this trial is testing

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 582
Testing effectiveness (Phase 2)Active Not RecruitingNCT06120140
What this trial is testing

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 305
Early research (Phase 1)Study completedNCT02228369
What this trial is testing

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
AstraZeneca 108
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)UnknownNCT02098954
What this trial is testing

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers

Who this might be right for
Carcinoma, Non-Small Cell LungEGFR Gene Mutation
Hunan Province Tumor Hospital 40
Early research (Phase 1)Study completedNCT02113813
What this trial is testing

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations
Astellas Pharma Global Development, Inc. 133
Large-scale testing (Phase 3)Study completedNCT04206072
What this trial is testing

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerEGFR Gene Mutation
Betta Pharmaceuticals Co., Ltd. 362
Next Page